Alberta Investment Management Corp Makes New $3.21 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG)

Alberta Investment Management Corp acquired a new stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 223,280 shares of the company’s stock, valued at approximately $3,206,000. Alberta Investment Management Corp owned approximately 0.18% of 10x Genomics as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of TXG. Assenagon Asset Management S.A. purchased a new position in 10x Genomics in the 4th quarter valued at about $26,308,000. ARK Investment Management LLC raised its holdings in shares of 10x Genomics by 15.4% during the third quarter. ARK Investment Management LLC now owns 10,750,345 shares of the company’s stock valued at $242,743,000 after acquiring an additional 1,436,582 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of 10x Genomics during the third quarter valued at approximately $27,778,000. FMR LLC lifted its position in shares of 10x Genomics by 2.7% in the third quarter. FMR LLC now owns 13,367,979 shares of the company’s stock valued at $301,849,000 after acquiring an additional 357,470 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of 10x Genomics by 355.0% in the third quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company’s stock worth $8,027,000 after acquiring an additional 277,355 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Stock Down 4.5 %

TXG stock opened at $11.56 on Friday. 10x Genomics, Inc. has a 52-week low of $10.80 and a 52-week high of $48.42. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of -7.61 and a beta of 1.85. The business has a fifty day moving average of $14.37 and a two-hundred day moving average of $17.15.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. As a group, sell-side analysts anticipate that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Barclays decreased their price objective on 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Monday, February 10th. Stifel Nicolaus decreased their price target on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Leerink Partners lowered shares of 10x Genomics from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $25.00 to $12.00 in a research report on Thursday, February 13th. Canaccord Genuity Group cut their price objective on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of 10x Genomics in a report on Wednesday. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $20.57.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.